Powered by

-Exicure, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update

Nov 17, 2017 - ENP Newswire

SKOKIE - Exicure, Inc., a Delaware corporation (the 'Company'), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional Spherical Nucleic Acid (SNA) constructs, today reported its financial results for the third quarter ended September 30, 2017.

'The third quarter was a transformational period for the Company. We continued to advance two SNA drug candidates toward their Phase 1 clinical trials and began our life as a public company,' said David Giljohann, Chi...